Vivitra 375mg Injection

Vivitra 375mg Injection contains Trastuzumab as its active ingredient, which is indicated for the treatment of HER2-positive breast cancer. In patients with HER2 positivity, the breast cancer cells predominantly consist of HER2 proteins that facilitate the rapid growth of cancer tumors by acting as signals to the cancerous cells. This medication is also utilized for treating metastatic gastric cancer characterized by elevated levels of HER2 proteins.

HER2-positive breast cancers are typically more aggressive. The targeted therapy for HER2-positive breast cancer functions by specifically targeting the proteins responsible for the growth, development, and dissemination of cancer. It is essential to use effective birth control during treatment and for at least seven months following the last dose.

Vivitra 375mg Injection is not advised for individuals under 18 years of age, those with severe respiratory issues, or patients requiring oxygen therapy. It is crucial to inform your healthcare provider if you have any heart conditions, experience breathlessness, or have previously undergone any other cancer treatments. Ensure that you disclose all medications, including supplements and herbal products, you are currently taking before commencing treatment with this medication.